Biocartis deal shows block buyers taking greater care

ECM bankers have found investors more receptive to blocks than expected so far this year. Nonetheless, buyers have demanded more from sellers before they commit to a deal, a trend in evidence in the €55m share sale in Biocartis on Wednesday night.

  • By Sam Kerr
  • 24 Jan 2019

Berenberg, KBC and Kempen & Co were bookrunners on the transaction, which grew from an initial size of €45m by €10m.

The banks were able to attract two anchor investors to the deal, which launched early Wednesday evening.

The deal was priced at €11.10 per share, an 8.3% ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 JPMorgan 134,743.10 557 8.28%
2 Citi 127,287.75 499 7.83%
3 Bank of America Merrill Lynch 106,110.85 421 6.52%
4 Barclays 101,992.87 397 6.27%
5 Deutsche Bank 82,349.11 329 5.06%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Bank of America Merrill Lynch 11,525.35 30 7.19%
2 BNP Paribas 8,639.54 48 5.39%
3 UniCredit 8,606.13 45 5.37%
4 Deutsche Bank 8,298.69 30 5.18%
5 Commerzbank Group 7,837.68 40 4.89%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Morgan Stanley 4,430.39 19 11.21%
2 Goldman Sachs 4,006.06 15 10.14%
3 Citi 3,532.95 22 8.94%
4 JPMorgan 2,809.08 19 7.11%
5 UBS 2,241.39 12 5.67%